Medical Marijuana, Inc. Subsidiary Kannaway® Announces February 2021 as the Best Month in Company History for Japan Division
Medical Marijuana, Inc. (MJNA) announced that its subsidiary, Kannaway®, achieved record sales in February 2021, marking its best month in company history. Since entering the Japanese market in late 2019, Kannaway® has expanded its footprint, offering high-quality cannabidiol (CBD) products. The global CBD oil market is projected to reach $5.3 billion by 2025, with significant growth expected in Asia-Pacific. CEO Blake Schroeder and Japan Division GM Peter Dale highlighted the positive consumer response and ongoing growth potential, reinforcing their commitment to the market.
- Kannaway® experienced its best sales month ever in February 2021.
- Strong expansion in the Japanese market since late 2019.
- Projected growth of the global CBD oil market to $5.3 billion by 2025, indicating a favorable market environment.
- None.
SAN DIEGO, CA, March 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the Japanese division of its subsidiary Kannaway® had its best sales month ever in Company history in February 2021.
“When we first entered the Japanese market in late 2019, we were one of the first companies offering cannabidiol (CBD) products in the country and saw a great opportunity to give consumers the high-quality products they had been asking for,” said Kannaway® CEO Blake Schroeder. “Since then, our team has done tremendous work expanding our reach and footprint in Japan.”
The Japanese CBD market looks to continue rapidly expanding in the coming years. According to Research and Markets, the global CBD oil market is expected to reach
“While leading our team in Japan, I have seen the positive response to our offerings in the country first-hand. Our team has shown what can be done with hard work and a distinguishing product offering and I look forward to our further growth,” said Kannaway® Japan Division General Manager Peter Dale.
To learn more about Kannaway®, please visit the Company online at https://www.kannaway.com/.
About Kannaway®
Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.
About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations Contact:
Kathryn Brown
Account Supervisor
CMW Media
P. 858-264-6600
kathryn@cmwmedia.com
www.cmwmedia.com
Investor Relations Contact:
P. (858) 283-4016
Investors@medicalmarijuanainc.com
FAQ
What recent sales milestone did Medical Marijuana, Inc. achieve in Japan?
What is the current market outlook for CBD products in Japan?
When did Medical Marijuana, Inc. enter the Japanese market?
What is the stock symbol for Medical Marijuana, Inc.?
